

1 ***Strongyloides stercoralis* infection induces gut dysbiosis in chronic kidney disease patients**

2

3 Nguyen Thi Hai^{1,7,8}, Nuttanan Hongsrichan^{1,7}, Kitti Intuyod^{2,7}, Porntip Pinlaor^{3,7}, Manachai

4 Yingklang^{1,7}, Apisit Chaidee^{1,7}, Thatsanapong Pongking^{4,7}, Sirirat Anutrakulchai^{5,7}, Ubon

5 Cha'on^{6,7}, Somchai Pinlaor^{1,7,*}

6

7 ¹*Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,*

8 *Thailand*

9 ²*Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,*

10 *Thailand*

11 ³*Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of*

12 *Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand*

13 ⁴*Science Program in Biomedical Science, Khon Kaen University, Khon Kaen 40002, Thailand*

14 ⁵*Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,*

15 *Thailand*

16 ⁶*Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,*

17 *Thailand*

18 ⁷*Chronic Kidney Disease Prevention in the Northeastern Thailand, Khon Kaen 40002, Thailand*

19 ⁸*Department of Parasitology, Thai Nguyen University of Medicine and Pharmacy, Vietnam*

20

21 *Corresponding author:

22 Prof. Somchai Pinlaor,

23 Department of Parasitology,

24 Faculty of Medicine, Khon Kaen University,

25 Khon Kaen 40002, Thailand.

26 E-mail address: psomec@kku.ac.th

27

28 **Abstract**

29 **Background**

30 *Strongyloides stercoralis* infection typically causes severe symptoms in
31 immunocompromised patients. However, the progression of infection-driven chronic kidney
32 disease (CKD) is not understood fully. Recent studies have shown that gut dysbiosis plays an
33 important role in the progression of CKD. Hence, this study aims to investigate the effect of *S.*
34 *stercoralis* infection on the gut microbiome in CKD patients.

35 **Methodology/Principal Findings**

36 Among 838 volunteers from Khon Kaen Province, northeastern Thailand, 40 subjects
37 with CKD were enrolled and divided into two groups (*S. stercoralis*-infected and -uninfected)
38 matched for age, sex and biochemical parameters. Next-generation technology was used to
39 amplify and sequence the V3-V4 region of the 16S rRNA gene to provide a profile of the gut
40 microbiota. Results revealed that members of the *S. stercoralis*-infected group had lower gut
41 microbial diversity than was seen in the uninfected group. Interestingly, there was significantly
42 greater representation of some pathogenic bacteria in the *S. stercoralis*-infected CKD group,
43 including *Escherichia-Shigella* ($P = 0.013$), *Rothia* ($P = 0.013$) and *Aggregatibacter* ($P = 0.03$).
44 There was also a trend towards increased *Actinomyces*, *Streptococcus* and *Haemophilus* ($P >$
45 0.05) in this group. On the other hand, the *S. stercoralis*-infected CKD group had significantly
46 lower representation of SCFA-producing bacteria such as *Anaerostipes* ($P = 0.01$),

47 *Coprococcus_1* (0.043) and a non-significant decrease of *Akkermansia*, *Eubacterium rectale* and
48 *Eubacterium hallii* ($P > 0.05$) relative to the uninfected group. Interesting, the genera
49 *Escherichia-Shigella* and *Anaerostipes* exhibited opposing trends, which were significantly
50 related to sex, age, infection status and CKD stages. The genus *Escherichia-Shigella* was
51 significantly more abundant in CKD patients over the age of 65 years and infected with *S.*
52 *stercoralis*. A correlation analysis showed inverse moderate correlation between the abundance
53 of the genus of *Escherichia-Shigella* and the level of estimated glomerular filtration rate (eGFR).

54 **Conclusions/Significance**

55 Conclusion, the results suggest that *S. stercoralis* infection induced gut dysbiosis in the
56 CKD patients, which might be involved in CKD progression.

57 **Key words:** *Strongyloides stercoralis*, chronic kidney disease, gut microbiota, 16S rRNA
58 gene, next-generation technology.

59

60 **Author summary**

61 Human strongyloidiasis is caused by a soil-transmitted helminth, *Strongyloides*
62 *stercoralis*, which typically causes severe symptoms in immunocompromised. However the
63 relationship between *S. stercoralis* and chronic kidney disease patients (CKD) progression was
64 not known. This is the first study to investigate the gut microbiota of CKD patients with and
65 without *S. stercoralis* using high-throughput sequencing of the V3–V4 region of the 16S rRNA
66 gene. Infection with *S. stercoralis* was associated with reduced gut microbiota diversity than in
67 the uninfected group. In addition, infection with this nematode led to reduced abundance of
68 SCFA-producing bacteria and enrichment of pathogenic bacteria. In particular, there were

69 significant differences in abundance of the beneficial genus *Anaerostipes* (a decrease) and the
70 pathogenic taxon *Escherichia-Shigella* (an increase) in CKD patients infected with *S. stercoralis*
71 relative to controls. In the infected group, the representation of genus *Escherichia-Shigella* was
72 significant higher in patients over the age of 65 years. There was a significant inverse moderate
73 correlation of *Escherichia-Shigella* with the estimated glomerular filtration rate (eGFR).

74

75 **Introduction**

76 An imbalance within the microbiota in the gastrointestinal tract, termed gut dysbiosis,
77 contributes to the development and progression of many diseases including chronic kidney
78 disease (CKD) [1]. Many studies have shown a significant difference in the abundance of
79 bacterial populations in the gastrointestinal tract (GI) between CKD and control individuals.
80 Substantially lower proportions of *Bifidobacterium*, *Lactobacillaceae*, *Bacteroidaceae* and
81 *Prevotellaceae* were seen in CKD patients, including those undergoing hemodialysis, while the
82 proportions of *Enterobacteriaceae*, especially *Enterobacter*, *Klebsiella* and *Escherichia*, were
83 notably higher [2-5]. The production of uremic toxins (indoxyl sulphate (IS), trimethylamine-N-
84 oxide (TMAO)), which results from nutrient processing by gut microbiota, and the reduction of
85 fiber-derived short-chain fatty acids, are linked with CKD progression [6-8]. Recent studies have
86 found various factors involved in microbial dysbiosis and CKD, such as the use of antibiotics
87 [9], decreased consumption of dietary fiber [10], and oral iron intake [11]. However, many
88 etiological factors associated with CKD remain obscure [12], particularly those due to infection
89 with intestinal parasites.

90 The ability of GI parasitic infection to changes the gut microbiota and host-microbiota
91 interactions has been clearly identified. Infection with intestinal parasites either induced gut

92 dysbiosis or provided protection against dysbiosis and inflammatory disease [13]. *Strongyloides*
93 *stercoralis* is one of the most medically important parasites in northeastern Thailand, where the
94 prevalence of CKD is also high [14]. Typically, *S. stercoralis* infection causes only mild GI
95 symptoms. However, when immunity is suppressed by, for example, CKD, diabetes mellitus or
96 HIV infection, the parasite can rapidly multiply and eventually leads to hyperinfection and
97 disseminated strongyloidiasis, which is a life-threatening condition [15-18].

98 Recent studies have successfully demonstrated that *S. stercoralis* induces an increase in
99 bacterial diversity and changes faecal microbiota [19, 20]. By using metagenomic analysis,
100 microbial alpha diversity was found to increase, and beta diversity decrease, in the faecal
101 microbial profiles of *S. stercoralis*-infected individuals compared to uninfected. Faecal
102 metabolite analysis detected marked increases in the abundance of selected amino acids and
103 decrease in short-chain fatty acids in *S. stercoralis* infection, relative to uninfected controls [19].
104 Taken together, we therefore hypothesize that *S. stercoralis* infection changes gut microbiome,
105 contributing to progression of CKD.

106 To test this hypothesis, metagenomic analysis was done in patients with CKD to
107 investigate the changes in the gut microbiota that can be attributed to *S. stercoralis* infection. The
108 result from this study might be useful for identifying strategies for prevention of chronic kidney
109 disease development and progression.

110

111 **Methods**

112 **Study population, area and ethics statement**

113 The study was conducted between January 2017 and May 2018 at Donchang sub-district,
114 Khon Kaen Province, northeastern Thailand as a part of the Chronic Kidney Disease

115 Northeastern Thailand (CKDNET) project. Included in the study were individuals (>35 years of
116 age) of chronic kidney disease. Their diagnosis, done by a nephrologist [14], included clinically
117 proven impaired kidney structure or renal function, as detected using ultrasonography, and a
118 finding of reduced eGFR. The staging (stages 1 to 5) based on the estimated glomerular filtration
119 rate (eGFR) [21, 22] was estimated for each individual. In patients with eGFR >
120 60 ml/min/1.73 m², kidney damage was confirmed based on urine albumin-to-creatinine ratio
121 (UACR), hematuria and abnormal renal ultrasound. Stool examination was performed on CKD
122 patients using the modified formalin ethyl acetate concentration technique (FECT) and modified
123 agar plate culture (mAPC) as previously reported [23].

124 Exclusion criteria were as follows: use of antibiotics or probiotics, diabetes, autoimmune
125 disease, urinary tract infection, renal infection with other intestinal parasites. Twenty CKD
126 patients with *S. stercoralis* infection (Ss+) [24] met these criteria and were included. The control
127 group consisted of 20 CKD patients free of *S. stercoralis* infection (Ss-) who otherwise matched
128 the characteristics (including sex, age and biochemical factors) of the Ss+ group (Table 1). These
129 datasets were obtained from the medical records of CKDNET and from a recent study [23].
130 Absence of *S. stercoralis* infection in members of the control group was also confirmed using
131 PCR tests. The human ethical review committee of Khon Kaen University (HE631200) approved
132 the protocol of study.

133 **Sample collection, DNA extraction**

134 Faecal and serum samples (n=40) were collected from the CKD Northeast Thailand
135 project and kept at -20 °C until analysis. DNA was extracted from faecal samples using the
136 QIAamp Kit (Qiagen, Germany). A Nanodrop 2000 spectrophotometer (NanoDrop

137 Technologies, Wilmington, DE, USA) was used to measure DNA concentration and 1.5%
138 agarose gel electrophoresis was used to check the DNA quality.

139 **16S rRNA gene sequencing and analysis**

140 To confirm that V3-V4 regions (about 450-500 bp) of the prokaryotic 16S rRNA gene
141 could be amplified, PCR was used to amplify DNA from each faecal sample. Specific V3-V4
142 primers were used, V3-forward: 5'-CCTACGGGNGGCWGCAG and V4-reverse: 5'-
143 TACNVGGGTATCTAATCC [25]. Each reaction (20.1 μ L) contained 2 μ L of 10x buffer
144 $MgCl_2$, 0.4 μ L of 50mM $MgCl_2$, 0.6 μ L of 10mM dNTP, 1 μ L of 5 μ M of each primer, 0.1 μ L
145 Platinum *Taq* DNA polymerase and distilled water. The amplification profile was initial
146 denaturation at 94 °C for 5 min, at 94 °C for 40 sec, then 35 cycles of 52.8 °C for 30 sec, 72 °C
147 for 2 min, followed by a final extension at 72 °C for 10 min. PCR product was electrophoresed
148 in a 1.5% agarose gel to confirm the presence of a band of the expected size.

149 A sequencing library was generated for each sample using NEBNext® Ultra™ DNA
150 Library Prep Kit for Illumina (Thermo Scientific) following the manufacturer's
151 recommendations. The library quality was assessed on the Qubit® 2.0 Fluorometer (Thermo
152 Scientific) and Agilent Bioanalyzer 2100 system. Finally, the library was sequenced on an
153 Illumina platform and 250 bp paired-end reads were generated. Processing and quality control of
154 these reads used the following steps: 1) Data split (based on their unique barcode) and truncation
155 by cutting off the barcode and primer sequences; 2) Sequence assembly (Paired-end reads were
156 merged using FLASH [26] and generated the raw tags; 3) Data filtration (quality filtering on the
157 raw tags was performed to obtain high-quality clean tags [27] according to the QIIME(V1.7.0,
158 <http://qiime.org/index.html>) quality controlled process [28]; 4) Chimera removal (the tags were

159 compared with a reference database [29] using the UCHIME algorithm [30] to detect chimera
160 sequences, which were then removed [31].

161 Sequences sharing $\geq 97\%$ similarity were assigned to the same operational taxonomic unit
162 (OTU) by using Uparse v7.0.1001 [32] and species annotated by reference to the GreenGene
163 Database [33] based on RDP 3 classifier [34] algorithm to annotate taxonomic information.
164 Phylogenetic relationship construction was conducted using the MUSCLE software (Version
165 3.8.31) [35]. Information on abundance of each OTU was normalized relative to the sample with
166 the fewest sequences. Subsequent analyses of alpha diversity were performed based on this
167 normalized data. Alpha diversity indicates species diversity for a sample using six indices
168 (observed-species, Chao1, Shannon, Simpson, ACE and Good's coverage). All these indices
169 were calculated using QIIME (Version 1.7.0) and displayed with the help of R software (Version
170 2.15.3). To show beta diversity, weighted and unweighted UniFrac metrics were used to evaluate
171 differences of samples in species complexity by using QIIME software (Version 1.7.0). Principal
172 Coordinate Analysis (PCoA) was performed to visualize complex and multidimensional data.
173 PCoA analysis was done using the WGCNA package, stat packages and ggplot2 package in R
174 software (Version 2.15.3). Metastats was used to detect taxa with significant intra-group
175 variation. The potential biomarkers were detected by using LEfSe (linear discriminant analysis
176 (LDA) Effect Size) [36]. Raw data are available from Mendeley Data (DOI:
177 10.17632/hvbvrtc34x.1)

178 **Polymerase Chain Reaction (PCR)**

179 Conventional PCR was used to confirm the absence of *S. stercoralis* infection in
180 members of the control group (n=20). Primers were designed specifically to amplify a 125 bp
181 fragment from a *S. stercoralis* dispersed repetitive sequence, GenBank: AY08262 [37]. The

182 forward primer was SSC-F 5' CTCAGCTCCAGTAAAGCAACAG 3' and reverse primer was
183 SSC-R 5' AGCTGAATCTGGAGAGTG AAGA 3'. PCR amplification was performed in a 12.5
184 μ L volume with Dream Taq PCR Master-mix (Thermo Fisher Scientific, Vilnius, Lithuania), 1
185 μ L of each primer, 5 μ L of 9–155 ng/ μ L DNA, and PCR-grade water. The amplification profile
186 was initial denaturation at 95 °C for 10 min, followed by 35 cycles of 95 °C for 1 min, 60 °C for
187 1 min 30 s and 72 °C for 1 min; then a final extension at 72 °C for 10 min. To confirm
188 amplification and amplicon size, the PCR products were resolved on a 2% agarose gel stained
189 with ethidium bromide.

190 **Statistical analysis**

191 Statistical analyses including ANOVA, independent t-test, Welch's t-test, Kruskal-Wallis
192 test, Mann-Whitney U tests and Pearson's correlation coefficient were conducted using IBM
193 SPSS Statistics version 20 (IBM, Armonk, New York). Statistically significant features were
194 further examined with post-hoc tests (Tukey-Kramer) to determine which groups of profiles
195 differed from each other. Non-normal distribution data of two genera (*Anaerostipes* and
196 *Escherichia-Shigella*) in association with CKD were log-transformed into normal distributions.
197 Statistical significance and 95% confidence intervals (95%CI) were calculated and considered as
198 $P < 0.05$.

199

200 **Results**

201 **Study population characteristics**

202 Demographic, socioeconomic and clinical characteristics of CKD patients with and
203 without *S. stercoralis* infection were matched (Table 1). No significant differences in these
204 characteristics were found between the Ss+ and Ss– groups.

205 **Characterization of bacterial diversity and community structure**

206 In total, 1551 OTUs were identified based on the 97%-similarity rule, with an average of
207 477 OTUs per sample. Sequences were classified into 16 bacterial phyla, 26 classes, 45 orders,
208 72 families and 258 genera and 189 species (including unidentified species). The species
209 accumulation curves showed a saturation phase (Fig. 1). This indicates that the sample size was
210 sufficient to capture the overall microbiota structure.

211 The unweighted UniFrac distances, reflecting beta diversity, showed significant
212 differences between the Ss+ and Ss– groups ($P = 0.00019$). In terms of alpha diversity overall,
213 there were no significant differences in estimated OTU richness, Chao1, the ACE metric, the
214 Shannon diversity index and Good’s coverage, ($P > 0.05$) (Table 3). In contrast, the alpha
215 diversity in males in the Ss– group was significantly higher than in males in the Ss+ group
216 (Shannon diversity index, $P = 0.015$; Simpson diversity index, $P = 0.058$) (Fig 2B, C).

217 The principal coordinate analysis (PCoA) was used to illustrate the beta diversity based
218 on the unweighted UniFrac distances (Fig 2D). PCoA analysis revealed that the gut microbiota
219 of Ss+ subjects showed deviation from the Ss– group (Fig 2E).

220 LDA score showed the significantly in abundance between the two groups. The candidate
221 biomarker for the Ss– category was order Bradymonadales and for CKD with *S. stercoralis*
222 infection (Ss+) was species *E. coli*, genera *Escherichia-Shigella*, *Dialister*, family
223 Veillonellaceae and order Selenomonadales (Fig 3).

224 **Differences in bacterial abundance between the Ss+ and Ss– groups**

225 Proportions of sequence reads were compared between groups at the phylum and genus
226 levels using Metastats. At the phylum level, there were no significant differences (Fig 4). For
227 example, relative abundances of some principal taxa were: Firmicutes (Ss- 64.14% vs. Ss+
228 59.33%; $P = 0.39$), Proteobacteria (Ss- 15.01% vs. Ss+ 18.83%; $P = 0.50$), Bacteroidetes (Ss-
229 12.61% vs. Ss+ 12.68%; $P = 0.98$), Actinobacteria (Ss- 3.46% vs. Ss+ 4.34%; $P = 0.67$) and
230 Fusobacteria (Ss- 1.88% vs. Ss+ 3.81%; $P = 0.52$). However, at the genus level, 42 taxa were
231 differentially relative abundance (Table 4).

232 To study the similarity among different samples, clustering analysis was applied. The
233 unweighted pair group method with arithmetic mean (UPGMA), a type of hierarchical clustering
234 method widely used in ecology, Ss- vs. Ss+ samples tended to cluster separately (Fig 5).

235 **The trends of some bacteria in *S. stercoralis* infection**

236 Fig 6 shows the comparisons of abundance of some bacteria between Ss- and Ss+ groups
237 at the genus level, with pathogenic bacteria groups were increased in Ss+, such as: *Escherichia-*
238 *Shigella* (3.36% vs. 13.33%; $P < 0.05$), *Streptococcus* (0.97% vs. 2.18%; $P > 0.05$),
239 *Haemophilus* (0.46% vs 0.71%; $P > 0.05$), *Rothia* (0.024% vs. 0.11%; $P < 0.05$), *Actinomyces*
240 (0.038% vs. 0.067%; $P > 0.05$), *Aggregatibacter* (0.0013% vs. 0.025%; $P < 0.05$) and reducing
241 of some SCFA-producing bacteria were observed, such as: *Eubacterium rectale_group* (4.51%
242 vs. 3.78%; $P > 0.05$), *Eubacterium hallii_group* (1.24% vs. 0.94%; $P > 0.05$), *Anaerostipes*
243 (0.54% vs. 0.074%; $P < 0.05$), *Coprococcus_1* (0.11% vs. 0.057%; $P < 0.05$) and *Akkermansia*
244 (0.081% vs. 0.043%; $P > 0.05$).

245 ***Anaerostipes* and *Escherichia-Shigella* exhibit opposing trends in abundance**
246 **and correlate with sex, age and CKD stage**

247 Fig 7 shows the opposing trends in abundance in the genera *Anaerostipes* and
248 *Escherichia-Shigella*. The proportion of reads of *Anaerostipes* was lower in those aged over 65
249 years (Fig. 7A), in females (7B), and with increasingly advanced CKD stage (7C) and in those
250 infected with *S. stercoralis* (Fig. 7A, B, C). The contrary was observed in the case of
251 *Escherichia-Shigella*: higher proportions of sequence reads of this genus were seen in elderly
252 (>65 years) individuals (Fig. 7 D), in females (Fig. 7 E) and in those infected with *S. stercoralis*
253 (Fig. 7D, E, F). More reads of *Escherichia-Shigella* were seen with increasingly advanced CKD
254 stage (Fig. 7F).

255

256 Discussion

257 In this study, we first characterized the gut microbiota of CKD with and without *S.*
258 *stercoralis* using high-throughput sequencing of the V3–V4 region of the 16S rRNA gene. The
259 results showed that *S. stercoralis* infection altered gut microbiota composition in CKD patients,
260 leading to lower microbial diversity. This study also suggested that microbial candidate
261 biomarkers for CKD concurrent with *S. stercoralis* infection include *Escherichia coli* (genus
262 *Escherichia-Shigella*, phylum Proteobacteria) and the genus *Dialister* (family Veillonellaceae,
263 order Selenomonadales, class Negativicutes, phylum Firmicutes).

264 Our results revealed that gut microbiota was altered by *S. stercoralis* infection in CKD
265 patients. The alpha-diversity indices (Chao1, the ACE metric, the Shannon diversity index,
266 Good's coverage) did not significantly differ between the two groups. However, the Shannon
267 diversity index in males (n=12) in Ss+ group was significantly lower than in the Ss- group. In
268 addition, the beta diversity, based on the unweighted UniFrac distances, was significantly lower
269 in the Ss+ group, suggesting a decrease in ecological diversity in CKD concurrent with *S.*

270 *stercoralis* infection. These slight differences spanned all taxonomic levels of the microbiota. At
271 the phylum level, abundance of Firmicutes was reduced while abundance of Proteobacteria and
272 Fusobacteria increased in Ss+ subjects. At the family level, there was an increase of
273 Clostridiaceae, Streptococcaceae, Desulfovibrionaceae and Enterobacteriaceae in the Ss+ group.
274 A previous study demonstrated that these families were associated with trimethylamine (TMA)
275 production [38]. The high abundances of families Enterobacteriaceae, Clostridiaceae
276 and Veillonellaceae in Ss+ subjects are in agreement with a previous study [39]. These bacteria
277 are associated with increasing the fecal pH [39] to a level where most opportunistic bacterial
278 pathogens prefer to grow [40]. The change of microbiota composition that we observed
279 may influence the environment in the gut, suggesting that *S. stercoralis* infection may influence
280 the microbiota and modulate the pH of the gut environment.

281 Forty-two genera showed contrasting abundances between the two groups. Interestingly,
282 there were significant increases of pathogenic bacteria including *Escherichia-Shigella*, *Rothia*
283 and *Aggregatibacter* and some increase of *Actinomyces*, *Streptococcus* and *Haemophilus* in CKD
284 patients infected with *S. stercoralis* compared to uninfected controls. In contrast, significant
285 reduction of some SCFA-producing bacteria, such as *Anaerostipes* and *Coprococcus_1* and some
286 decrease of *Akkermansia*, *Eubacterium_rectale_group* and *Eubacterium_hallii_group* were noted
287 in the Ss+ group. Specifically, abundance of the genus *Escherichia-Shigella* is known to be
288 positively correlated with uremic toxins such as trimethylamine-N-oxide and indoxyl sulfate
289 [41]. Our results demonstrated a significant inverse correlation of *Escherichia-Shigella* with the
290 estimated glomerular filtration rate (eGFR $r = -0.37$, $P = 0.018$). eGFR is one criterion for
291 diagnosis and staging of CKD. Thus, high abundance of *Escherichia-Shigella* was correlated
292 with low eGFR value and higher CKD stage (Figure 6). In addition, *Enterobacteriaceae* and *E.*

293 *coli* are markedly more abundant in individuals with impaired kidney function as demonstrated
294 previously [42], highlighting that there is an association between the genus *Escherichia-Shigella*
295 and CKD with concurrent *S. stercoralis* infection.

296 Interestingly, the genus *Anaerostipes* was less abundant in CKD patients with concurrent
297 *S. stercoralis* infection than in those without. Members of this genus are Gram-variable, obligate
298 anaerobes which produce acetate, butyrate and lactate from glucose fermentation [43]. Our
299 findings were partially consistent with those of a previous study, which found that *Anaerostipes*
300 had low relative abundance in CKD in an animal model and noted that this genus was negatively
301 correlated with amount of intestinal urea. Nephrectomized mice with low levels
302 of *Anaerostipes* exhibited negative effects on kidney parameters (BUN and creatinine) [44].
303 However, we found no correlation here between *Anaerostipes* and kidney parameters. This may
304 be due to the limited sample size. Recent research indicated that elevated levels
305 of *Anaerostipes* led to increased eGFR and improvement in renal function [45]. Furthermore, the
306 relative abundance of the genus *Anearostipes* was markedly reduced in nonsurvivors with end-
307 stage kidney disease (ESKD) [46]. Specifically, we found that one species, *Anaerostipes hadrus*,
308 an important microbe in maintaining intestinal metabolic balance [47], was significantly reduced
309 in CKD with concurrent *S. stercoralis* infection.

310 A previous study using a rat model revealed that increased levels of *Rothia* were
311 positively associated with creatinine levels in acute kidney injury and with severity of kidney
312 damage [48]. *Rothia* spp. are Gram-positive cocco-bacilli that cause a wide range of serious
313 infections, especially in immunocompromised hosts. *Rothia* is often identified in blood cultures
314 from patients with bacteremia [49]. In this study, we found a positive correlation between *Rothia*
315 and the genus *Streptococcus* ($r = 0.47$, $P = 0.002$). A similar relationship was observed in a

316 recent study, which found that the log-ratio between the presence of the genera *Rothia* and
317 *Streptococcus* genera was the best predictor of creatinine level [48].

318 The main SCFA-producing bacteria in humans [50] include *Faecalibacterium prausnitzii*
319 (butyrate-producing bacteria in the phylum Firmicutes), *Eubacterium rectale* and *E. hallii*
320 (family Lachnospiraceae) and *Anaerostipes* spp. (sugar/lactate-utilizing bacteria producing
321 butyrate from lactate and acetate) were all less abundant in *S. stercoralis* infection. A previous
322 study observed a decrease in the level of serum SCFAs in CKD patients and an inverse
323 correlation between butyrate level and renal function [51]. Our study suggested that SCFA-
324 producing bacteria are depleted in CKD with concurrent *S. stercoralis* infection, which may
325 affect CKD progression. However, further studies are needed to confirm this association.

326 Our study has strengths and limitations. An important strength of this study is that we
327 used groups that were pair-matched for sex, age and biochemical factors. However, we did not
328 obtain data for concentrations of uremic toxins (TMAO and IS) or for amounts of SCFAs.
329 Moreover, we did not record the clinical manifestation of *S. stercoralis* infection in CKD patient
330 so we were not able to show the association between some pathogenic bacteria and *S. stercoralis*
331 infection in CKD. In addition, the sample size in this study was small due to the fact that
332 participant who infected with single *S. stercoralis* and got CKD which was limited. These affect
333 the estimation of microbiome alpha diversity and other statistical power in analyses.

334 **Conclusions**

335 This study suggests that *S. stercoralis* infection reduces the diversity of the gut
336 microbiota in CKD patients. An increased abundance of harmful bacteria and reduction of some
337 SCFA-producing bacteria in *S. stercoralis* infection were found. In addition, the abundance of
338 members of the genus *Escherichia-Shigella* was significantly and inversely correlated with

339 eGFR levels. Significant elevation of members of this genus in CKD patients with *S. stercoralis*
340 infection may indicate potential diagnostic markers for CKD in *S. stercoralis*-endemic areas.
341 Thus, we suggest that these changes in the composition of the gut microbiome in *S. stercoralis*
342 infection may result in disruption of the gut barrier structure and absorption of harmful products
343 that can contribute to toxicity, inflammation and malnutrition, contributing to CKD progression.
344 Future metabolomics studies are required to unravel the relationship between CKD and *S.*
345 *stercoralis* infection.

346

347 **Funding**

348 This study was supported by Research Program (RP65-2-001), CKDNET (grant no.
349 CKDNET2559007) and Invitation research grant, Faculty of Medicine Research Grant
350 (IV63136), Khon Kaen University. S.A. acknowledged research funds from Thailand Science
351 Research and Innovation (TSRI), through Program Management Unit for Competitiveness
352 (PMUC), number C10F630030.

353

354 **Acknowledgments**

355 N.T.H. thanks the scholarship under the Doctoral Training Program from Research
356 Affairs, Medicine Faculty and Graduate School, Khon Kaen University, Thailand. We would like
357 to thank to all of the people who voluntarily participated in this study. We also acknowledge
358 Prof. David Blair from Publication Clinic KKU, Thailand, for his comments and editing the
359 manuscript.

360

361 **Author contributions**

362 **Conceptualization:** Nuttanan Hongsrichan, Porntip Pinlaor, Somchai Pinlaor.

363 **Formal analysis:** Nguyen Thi Hai, Nuttanan Hongsrichan, Kitti Intuyod, Manachai Yingklang,

364 Apisit Chaidee, Thatsanapong Pongking, Porntip Pinlaor, Sirirat Anutrakulchai, Ubon Cha'on,

365 Somchai Pinlaor.

366 **Funding acquisition:** Nguyen Thi Hai, Sirirat Anutrakulchai, Ubon Cha'on, Somchai Pinlaor.

367 **Investigation:** Nguyen Thi Hai, Nuttanan Hongsrichan, Kitti Intuyod, Porntip Pinlaor, Manachai

368 Yingklang, Apisit Chaidee, Thatsanapong Pongking, Sirirat Anutrakulchai, Ubon Cha'on,

369 Somchai Pinlaor.

370 **Project administration:** Somchai Pinlaor.

371 **Resources:** Sirirat Anutrakulchai, Ubon Cha'on, Somchai Pinlaor.

372 **Supervision:** Nuttanan Hongsrichan, Porntip Pinlaor, Somchai Pinlaor.

373 **Visualization:** Nguyen Thi Hai, Thatsanapong Pongking, Kitti Intuyod, Apisit Chaidee.

374 **Writing - original draft:** Nguyen Thi Hai.

375 **Writing - review & editing:** Nguyen Thi Hai, Nuttanan Hongsrichan, Somchai Pinlaor.

376

377 **References**

378 1. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney

379 disease: challenges and opportunities. *Transl Res.* 2017;179:24-37. pmid: 27187743.

380 2. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation

381 of uremic toxins in the blood and their precursors in the feces after oral administration of

- 382 Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.
383 Nephron. 1996;74(2):349-55. pmid: 8893154.
- 384 3. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated
385 with microinflammation in end-stage renal disease patients. Nephrology (Carlton).
386 2012;17(8):733-8. pmid: 22817644.
- 387 4. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease
388 alters intestinal microbial flora. Kidney Int. 2013;83(2):308-15. pmid: 22992469.
- 389 5. De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, et al.
390 Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS
391 One. 2014;9(6):e99006. pmid: 24922509.
- 392 6. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic
393 kidney disease in the United States. Jama. 2007;298(17):2038-47. pmid: 17986697.
- 394 7. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am
395 Soc Nephrol. 2014;25(4):657-70. pmid: 24231662.
- 396 8. Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease-
397 and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty
398 acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230-7. pmid:
399 24643131.
- 400 9. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L.
401 Short-term antibiotic treatment has differing long-term impacts on the human throat and gut
402 microbiome. PLoS One. 2010;5(3):e9836. pmid: 20352091.

- 403 10. Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G. Food intake characteristics of
404 hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr.
405 2002;12(1):17-31. pmid: 11823990.
- 406 11. Fouque D, Cruz Casal M, Lindley E, Rogers S, Pancirova J, Kernc J, et al. Dietary trends
407 and management of hyperphosphatemia among patients with chronic kidney disease: an
408 international survey of renal care professionals. J Ren Nutr. 2014;24(2):110-5. pmid:
409 24447438.
- 410 12. Lunyera J, Mohottige D, Von Isenburg M, Jeuland M, Patel UD, Stanifer JW. CKD of
411 uncertain etiology: a systematic review. Clin J Am Soc Nephrol. 2016;11(3):379-85. pmid:
412 26712810.
- 413 13. Leung JM, Graham AL, Knowles SCL. Parasite-Microbiota interactions with the vertebrate
414 gut: synthesis through an ecological lens. Front Microbiol. 2018;9:843. pmid: 29867790.
- 415 14. Cha'on U, Wongtrangan K, Thinkhamrop B, Tatiyanupanwong S, Limwattananon C,
416 Pongskul C, et al. CKDNET, a quality improvement project for prevention and reduction of
417 chronic kidney disease in the Northeast Thailand. BMC Public Health. 2020;20(1):1299.
418 pmid: 32854662.
- 419 15. De Souza JN, Soares B, Goes LL, Lima CS, Barreto N, Jacobina BS, et al. Case report:
420 *Strongyloides stercoralis* hyperinfection in a patient with HTLV-1: a case report of an
421 infection with filariform and rhabditiform larvae, eggs, and free-living adult females. Am J
422 Trop Med Hyg. 2018. pmid: 30277207.
- 423 16. Winnicki W, Eder M, Mazal P, Mayer FJ, Sengölge G, Wagner L. Prevalence of
424 *Strongyloides stercoralis* infection and hyperinfection syndrome among renal allograft
425 recipients in Central Europe. Scientific Reports. 2018;8(1):15406.

- 426 17. Qu TT, Yang Q, Yu MH, Wang J. A fatal *Strongyloides stercoralis* hyperinfection
427 syndrome in a patient with chronic kidney disease: a case report and literature review.
428 Medicine (Baltimore). 2016;95(19):e3638. pmid: 27175679.
- 429 18. Krolewiecki A, Nutman TB. Strongyloidiasis: a neglected tropical disease. Infect Dis Clin
430 North Am. 2019;33(1):135-51. pmid: 30712758.
- 431 19. Jenkins TP, Peachey LE, Ajami NJ, MacDonald AS, Hsieh MH, Brindley PJ, et al.
432 *Schistosoma mansoni* infection is associated with quantitative and qualitative modifications
433 of the mammalian intestinal microbiota. Sci Rep. 2018;8(1):12072. pmid: 30104612.
- 434 20. Pane S, Sacco A, Iorio A, Romani L, Putignani L. *Strongyloides stercoralis* infestation in a
435 child: how a nematode can affect gut microbiota. International Journal of Molecular
436 Sciences. 2021;22(4):2131. pmid: doi:10.3390/ijms22042131.
- 437 21. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic
438 nature of CKD. Nat Rev Nephrol. 2017;13(6):344-58. pmid: 28435157.
- 439 22. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US
440 commentary on the 2012 KDIGO clinical practice guideline for the evaluation and
441 management of CKD. Am J Kidney Dis. 2014;63(5):713-35. pmid: 24647050.
- 442 23. Kaewrat W, Sengthong C, Yingklang M, Intuyod K, Haonon O, Onsurathum S, et al.
443 Improved agar plate culture conditions for diagnosis of *Strongyloides stercoralis*. Acta Trop.
444 2020;203:105291. pmid: 31816322.
- 445 24. Fellows R, Denizot J, Stellato C, Cuomo A, Jain P, Stoyanova E, et al. Microbiota derived
446 short chain fatty acids promote histone crotonylation in the colon through histone
447 deacetylases. Nat Commun. 2018;9(1):105. pmid: 29317660.

- 448 25. Itthitaetrakool U, Pinlaor P, Pinlaor S, Chomvarin C, Dangtakot R, Chaidee A, et al. Chronic
449 *Opisthorchis viverrini* infection changes the liver microbiome and promotes *Helicobacter*
450 growth. PLOS ONE. 2016;11(11):e0165798.
- 451 26. Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome
452 assemblies. Bioinformatics. 2011;27(21):2957-63. pmid: 21903629.
- 453 27. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, et al. Quality-
454 filtering vastly improves diversity estimates from Illumina amplicon sequencing. Nat
455 Methods. 2013;10(1):57-9. pmid: 23202435.
- 456 28. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al.
457 QIIME allows analysis of high-throughput community sequencing data. Nature methods.
458 2010;7(5):335-6. pmid: 20383131.
- 459 29. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal
460 RNA gene database project: improved data processing and web-based tools. Nucleic Acids
461 Res. 2013;41(Database issue):D590-6. pmid: 23193283.
- 462 30. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and
463 speed of chimera detection. Bioinformatics. 2011;27(16):2194-200. pmid: 21700674.
- 464 31. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, et al. Chimeric 16S
465 rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons.
466 Genome Res. 2011;21(3):494-504. pmid: 21212162.
- 467 32. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads.
468 Nature Methods. 2013;10(10):996-8.

- 469 33. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a
470 chimera-checked 16S rRNA gene database and workbench compatible with ARB. Applied
471 and environmental microbiology. 2006;72(7):5069-72. pmid: 16820507.
- 472 34. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of
473 rRNA sequences into the new bacterial taxonomy. Applied and environmental microbiology.
474 2007;73(16):5261-7. pmid: 17586664.
- 475 35. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
476 Nucleic Acids Research. 2004;32(5):1792-7.
- 477 36. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
478 biomarker discovery and explanation. Genome Biology. 2011;12(6):R60.
- 479 37. Formenti F, La Marca G, Perandin F, Pajola B, Romano M, Santucci B, et al. A diagnostic
480 study comparing conventional and real-time PCR for *Strongyloides stercoralis* on urine and
481 on faecal samples. Acta Tropica. 2019;190:284-7.
- 482 38. Al-Obaide MAI, Singh R, Datta P, Rewers-Felkins KA, Salguero MV, Al-Obaidi I, et al.
483 Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers inpatients with
484 T2DM and advanced CKD. J Clin Med. 2017;6(9). pmid: 28925931.
- 485 39. Henrick BM, Hutton AA, Palumbo MC, Casaburi G, Mitchell RD, Underwood MA, et al.
486 Elevated fecal pH indicates a profound change in the breastfed infant gut microbiome due to
487 reduction of *Bifidobacterium* over the past century. mSphere.
488 2018;3(2):e00041-18.
- 489 40. Duar RM, Kyle D, Casaburi G. Colonization Resistance in the Infant Gut: the role of *B.*
490 *infantis* in reducing pH and preventing pathogen growth. High Throughput. 2020;9(2). pmid:
491 32230716.

- 492 41. Tomlinson JAP, Wheeler DC. The role of trimethylamine N-oxide as a mediator of
493 cardiovascular complications in chronic kidney disease. *Kidney International*.
494 2017;92(4):809-15.
- 495 42. Gryp T, Huys GRB, Joossens M, Van Biesen W, Glorieux G, Vaneechoutte M. Isolation and
496 quantification of uremic toxin precursor-generating gut bacteria in chronic kidney disease
497 patients. *Int J Mol Sci*. 2020;21(6). pmid: 32183306.
- 498 43. Schwiertz A, Hold GL, Duncan SH, Gruhl B, Collins MD, Lawson PA, et al. *Anaerostipes*
499 *caccae* gen. nov., sp. nov., a new saccharolytic, acetate-utilising, butyrate-producing
500 bacterium from human faeces. *Syst Appl Microbiol*. 2002;25(1):46-51. pmid: 12086188.
- 501 44. Chaves LD, McSkimming DI, Bryniarski MA, Honan AM, Abyad S, Thomas SA, et al.
502 Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis.
503 *Am J Physiol Renal Physiol*. 2018;315(3):F487-f502. pmid: 29693447.
- 504 45. Mazidi M, Shekoohi N, Covic A, Mikhailidis DP, Banach M. Adverse impact of
505 *Desulfovibrio spp.* and beneficial role of *Anaerostipes spp.* on renal function: insights from a
506 mendelian randomization analysis. *Nutrients*. 2020;12(8):2216. pmid:
507 doi:10.3390/nu12082216.
- 508 46. Lin TY, Wu PH, Lin YT, Hung SC. Gut dysbiosis and mortality in hemodialysis patients.
509 *NPJ Biofilms Microbiomes*. 2021;7(1):20. pmid: 33658514.
- 510 47. Kant R, Rasinkangas P, Satokari R, Pietila TE, Palva A. Genome sequence of the butyrate-
511 producing anaerobic bacterium *Anaerostipes hadrus* PEL 85. *Genome Announc*. 2015;3(2).
512 pmid: 25838483.

- 513 48. Andrianova NV, Popkov VA, Klimenko NS, Tyakht AV, Baydakova GV, Frolova OY, et al.
514 Microbiome-metabolome signature of acute kidney injury. *Metabolites*. 2020;10(4). pmid:
515 32260384.
- 516 49. Ramanan P, Barreto JN, Osmon DR, Tosh PK. *Rothia* bacteremia: a 10-year experience at
517 Mayo Clinic, Rochester, Minnesota. *J Clin Microbiol*. 2014;52(9):3184-9. pmid: 24951810.
- 518 50. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et
519 al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its
520 relevance for inflammatory bowel diseases. *Frontiers in Immunology*. 2019;10(277).
- 521 51. Wang S, Lv D, Jiang S, Jiang J, Liang M, Hou F, et al. Quantitative reduction in short-chain
522 fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. *Clin*
523 *Sci (Lond)*. 2019;133(17):1857-70. pmid: 31467135.
- 524 52. Morimoto J, Kaneoka H, Sasatomi Y, Sato YN, Murata T, Ogahara S, et al. Disseminated
525 strongyloidiasis in nephrotic syndrome. *Clin Nephrol*. 2002;57(5):398-401. pmid: 12036202.

526

527

528

529

530 **Figure & Legend**

531 **Table 1. Characteristics of chronic kidney disease patients.**

532

533 Data are presented as mean \pm standard deviation of the mean. Independent t-tests and Mann-
 534 Whitney U tests (a) were used to calculate *P* values.

Parameters	Normal range	Ss- (n=20)	Ss+ (n=20)	<i>P</i> value
Sex	Male	12	12	
	Female	8	8	
Age years		64.60 \pm 11.3	64.85 \pm 13.4	0.95
BMI kg/m ²	18-25	23.6 \pm 3.8	22.14 \pm 4.1	0.26
MCV fL	79.0-94.8	80.53 \pm 8.9	83.45 \pm 9.7	0.33
MCH pg	25.6-32.2	26.25 \pm 3.7	27.48 \pm 3.7	0.30
MCHC g/dL	32.2-36.5	32.49 \pm 1.2	32.84 \pm 0.9	0.29
eGFR ml/min/1.73 m ²	\geq 90	73.3 \pm 20.3	71.3 \pm 25.4	0.78
Neutrophil (NE)%	50-70	52.00 \pm 7.0	48.50 \pm 13.6	0.31
Lymphocyte (LY)%	20-40	31.99 \pm 6.6	33.42 \pm 10.0	0.60
Monocyte (MO)%	2-8	7.56 \pm 1.8	7.27 \pm 1.9	0.63
Eosinophil [52]%	1-3	7.60 \pm 4.5	9.98 \pm 8.7	0.62a
Basophils (BA) %	0-1	0.78 \pm 0.4	0.84 \pm 0.5	0.84a
Glucose mg/dL	70-100	89.3 \pm 11.2	90.45 \pm 13.0	0.90a
LDL Cholesterol mg/dL	10-150	121.0 \pm 34.4	114.75 \pm 28.4	0.94a
Hemoglobin g/dL	13.0-16.7	12.18 \pm 2.4	12.44 \pm 1.8	0.70
Hematocrit %	34-51	37.8 \pm 5.7	37.7 \pm 4.9	0.95
Uric acid mg/dL	2.7-7.0	6.14 \pm 1.6	5.85 \pm 1.6	0.57
Urine creatinine mg/dL	25-400	128.89 \pm 63.2	114.82 \pm 61.7	0.43a
Microalbumin mg/dL	0.2-1.9	6.90 \pm 18.3	5.55 \pm 6.2	0.29a
UACR mg/g	<30	50.02 \pm 114.8	140.43 \pm 229.2	0.096a
Hemoglobin A1c %	4.6-6.5	5.50 \pm 0.6	5.45 \pm 0.5	0.75
Bpsys mmhg	<140	125.94 \pm 17.7	129.56 \pm 16.5	0.54
Bpdia mmhg	<90	81.38 \pm 7.87	76.33 \pm 9.43	0.46

535 Abbreviations: BMI, body mass index; Bpsys mmhg, Blood pressure systolic (mmhg); Bpdia
 536 mmhg, Blood pressure diastolic (mmhg); MCV, Mean corpuscular volume; MCH, Mean

537 Corpuscular Hemoglobin; MCHC, mean corpuscular hemoglobin concentration; U,
538 urine; UACR, urine albumin-to-creatinine ratio.

539

540 **Table 2. Alpha diversity of the gut microbiota in Ss- and Ss+ groups, calculated according**
541 **to several indices.**

Group	No. of Reads	No. of OTUs	Good's (%)	ACE	Chao 1	PD whole tree	Shannon	Simpson
Ss-	73173.3	483.7	0.99765	515.713	517.886	32.7308	5.25775	0.9182
Ss+	74770.1	470.15	0.9976	507.982	504.266	32.5759	4.82045	0.88145
<i>P</i>		0.45	0.706a	0.78	0.76a	0.92	0.08a	0.218a

542 Independent t-tests and Mann-Whitney U tests (a) were used to calculate *P* values.

543

544 **Table 3. Taxa in the gut microbiome differing significantly between CKD patients with and**
545 **without *S. stercoralis*.**


Phylum	Family	Genus	Change in abundance	
			Ss+	Ss-
Actinobacteria	Coriobacteriaceae	<i>Atopobium</i>	↑	
		<i>Coriobacteriaceae_UCG-003</i>	↑	
		<i>Gordonibacter</i>		↑
		<i>unidentified_Coriobacteriaceae</i>		↑
	Corynebacteriaceae	<i>Corynebacterium</i>	↑	
	Micrococcaceae	<i>Rothia</i>	↑	
Bacteroidetes	Porphyromonadaceae	<i>Petrimonas</i>	↑	
		<i>Proteiniphilum</i>		↑
	Prevotellaceae	<i>Paraprevotella</i>		↑
		<i>Prevotella_1</i>	↑	

Cyanobacteria	unidentified_Gastranaerophilales	<i>unidentified_Gastranaerophilales</i>		↑	
Firmicutes	Carnobacteriaceae	<i>Lacticigenium</i>	↑		
	Leuconostocaceae	<i>Leuconostoc</i>		↑	
	Christensenellaceae	<i>Christensenella</i>		↑	
	Eubacteriaceae	<i>Anaerofustis</i>		↑	
	Family_XI	<i>Gallicola</i>		↑	
		<i>Peptoniphilus</i>		↑	
		<i>Tissierella</i>		↑	
	Lachnospiraceae	<i>[Eubacterium]_xylanophilum_group</i>			↑
		<i>Anaerosporobacter</i>			↑
		<i>Anaerostipes</i>			↑
		<i>Coproccoccus_1</i>			↑
		<i>Lachnospiraceae_UCG-010</i>		↑	
		<i>Tyzzarella_3</i>			↑
	Peptostreptococcaceae	<i>Paeniclostridium</i>			↑
	Ruminococcaceae	<i>Pseudoflavonifractor</i>			↑
		<i>Ruminiclostridium_1</i>		↑	
		<i>Ruminococcaceae_UCG-011</i>		↑	
	Erysipelotrichaceae	<i>Erysipelotrichaceae_UCG-003</i>			↑
		<i>Erysipelotrichaceae_UCG-004</i>			↑
		<i>unidentified_Erysipelotrichaceae</i>			↑
Veillonellaceae	<i>Dialister</i>		↑		
Fusobacteria	Leptotrichiaceae	<i>Leptotrichia</i>	↑		
Proteobacteria	Neisseriaceae	<i>Eikenella</i>	↑		
	Rhodocyclaceae	<i>Dechlorobacter</i>	↑		
	Desulfobulbaceae	<i>Desulfobulbus</i>	↑		
	Cardiobacteriaceae	<i>Cardiobacterium</i>	↑		
	Enterobacteriaceae	<i>Cronobacter</i>		↑	
	Enterobacteriaceae	<i>Escherichia-Shigella</i>	↑		

	Pasteurellaceae	<i>Actinobacillus</i>	↑	
	Pasteurellaceae	<i>Aggregatibacter</i>	↑	
	Xanthomonadaceae	<i>Arenimonas</i>	↑	

546

547



548

549 **Fig 1. Species accumulation curve.**

550 X-axis: Number of samples, Y-axis: number of OTUs. Following an initial sharp rise in the

551 number of OTUs as number of samples increases, there is a levelling of the plot. The narrow

552 spread of the boxplots as the total number of samples is approached indicates that the number of


553 samples was adequate to capture most of the microbial diversity present.

554

555

556

557



558

559

560 **Fig 2. Comparison of alpha diversity indexes and beta diversity in CKD patients with and**

561 **without *S. stercoralis* infection.**

562 (A) Shannon index (B) Shannon index in males (C) Simpson index in males. (D) Boxplot based

563 on unweighted UniFrac distance. (E) Principal coordinate analysis (PCoA).

564

565

566


567

568

569

570

571



Cladogram

572

573

574 **Fig 3. Linear discriminant analysis (LDA).**

575 The histogram of the LDA scores presents taxa (potential biomarkers) whose abundance differed

576 significantly among groups (Ss+ vs. Ss-) Oder Bradymonadales in Ss- (green colour). Species

577 *E. coli* belong to genus *Escherichia-Shigella*; genus *Dialister* belong to order Selenomonadales,

578 class Negativicutes and family Veillonellaceae in Ss+ (red colour).

579

580

581

582

583

584

585


586

587

588

589

590




591

592

593 **Fig 4. The gut microbiota composition.**

594 (A) and (B), Control group compared with *S. stercoralis*-infection group (Ss+) at the phylum and

595 genus levels, respectively.



596

597

598 **Fig 5. Unweighted pair group method with arithmetic mean (UPGMA).**


599 UPGMA cluster tree based on unweighted UniFrac distances between CKD patients with or

600 without *S. stercoralis* infection. The red branches present *S. stercoralis* infection (Ss+) subject

601 and the dark blue branches indicate un-infection (Ss-) ones.

602


603



604
605 **Fig 6. Comparisons of abundance (numbers of sequence reads) of some bacteria between**
606 **Ss- and Ss+ group.**

607 Pathogenic bacteria: *Escherichia-Shigella*, *Streptococcus*, *Haemophilus*, *Rothia*, *Actinomyces*,
608 *Aggregatibacter*. SCFA-producing bacteria: *Eubacterium rectale_group*, *Eubacterium*
609 *hallii_group*, *Anaerostipes*, *Coprococcus_1*, *Akkermansia*.

610




611 **Fig 7. Opposing trends in abundance of two genera, *Anaerostipes* and *Escherichia-Shigella*.**

612 (A), (D) Different trend related to age (B), (E) sex and (C), (F) CKD stages. * $P < 0.05$,


613 ** $P < 0.01$, *** $P < 0.001$. Analysis of the difference among groups of sex, age and CKD stages

614 based on one-way ANOVA test.

615




Figure




Cladogram

- a: f_Veillonellaceae
- b: o_Selenomonadales
- c: c_Negativicutes
- d: o_Bradymonadeles


- Ss+
- Ss-




Figure



Figure




Figure




Figure

Observed species



Figure



Figure